Many drugs including biologicals require special storage and handling prior to their use because of stability issues - a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed – a distribution strategy referred to as the ‘Cold Chain’. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. The need to reconstitute lyophilized drugs at the point of administration is driving the growth of dual chamber syringes and injectors – devices that allow reconstitution to take place within the device prior to injection. As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.
Provides assessments of dual chamber syringes and injection devices and analyzes their impact on markets for therapeutic injectable lyophilized drugs
Analyzes therapeutic demand drivers and evaluates the potential of dual chamber syringes and injector systems
Analyzes device selection factors, technologies and market development issues
Provides market data and forecasts to 2015
Profiles dual chamber syringe and injector device suppliers, their product activities, business strategies, and corporate alliances and affiliations
Assesses the importance of pharma-device alliances and design partnerships on injectable drug–device combination products
Evaluates the impact of economic, technology, and regulatory factors